The Application of Quality Risk Management to the Bacterial Endotoxins Test: Use of Hazard Analysis and Critical Control Points

References

1. 1.↵
   The Rules Governing Medicinal Products in the European Union, Vol. 4, Part I (Basic Requirements for Medicinal Products); European commission; available at http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm.
2. 2.↵
   Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Title 21, Part 211; U.S. Food and Drug Administration; available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm.
3. 3.↵
   1. van Leeuwen J. F.,
   2. Nuta M. J.,
   3. de Kaste D.,
   4. Odekerken-Rombouts Y. M.,
   5. Vredenbregt M. J.,
   6. Barends D. M.

   Risk analysis by FMEA as an element of analytical validation. J. Pharm. Biomed. Anal. 2009, 50 (5), 1085–1087.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. McCullough K.

   The Bacterial Endotoxins Test—A Practical Guide, 1st ed.; DHI: Moore, OK, 2011.
5. 5.↵
   1. Saghee M. R.,
   2. Sandle T.,
   3. Tidswell E. C.

   1. Sandle T.

   Risk Management in Pharmaceutical Microbiology. In Saghee M. R., Sandle T., Tidswell E. C. Microbiology and Sterility Assurance in Pharmaceuticals and Medical Devices; Business Horizons: New Delhi, India, 2011; pp 553–588.
6. 6.↵
   Quality Risk Management (ICH Q9). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005; available at http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
7. 7.↵
   1. Whyte W.

   A cleanroom contamination control system. Eur. J. Parent. Sci. 2002, 7 (2) 55–61.

   OpenUrl
8. 8.↵
   1. Tidswell E. C.,
   2. McGarvey B.

   Quantitative risk modeling in aseptic manufacture. PDA J. Pharm. Sci. Technol. 2006, 60 (5), 267–283.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Agalloco J.,
   2. Akers J. E.

   Risk analysis for aseptic processing: the Akers-Agalloco method. Pharm. Technol. 2005, 29 (11), 74–88.

   OpenUrl
10. 10.↵
    1. Williams K. L.

    Endotoxins: Pyrogens, LAL Testing and Depyrogenation, 3rd ed.; Informa Healthcare: New York, 2007; pp 191–217.
11. 11.↵
    1. Jahnke M.,
    2. Kühn K. D.

    Use of the hazard analysis and critical control points (HACCP) risk assessment on a medical device for parenteral application. PDA J. Pharm. Sci. Technol. 2003, 57 (1) 32–42.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Bonan B.,
    2. Martelli N.,
    3. Berhoune M.,
    4. Maestroni M. L.,
    5. Havard L.,
    6. Prognon P.

    The application of hazard analysis and critical control points and risk management in the preparation of anti-cancer drugs. International Journal for Quality in Health Care 2009, 21 (1), 44–50.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    PDA Technical Report No. 54. Implementation of Quality Risk Management for pharmaceutical and biotechnology manufacturing operations; Parenteral Drug Association: Bethesda, MD, 2012.
14. 14.↵
    1. Oldenhof M. T.,
    2. van Leeuwen J. F.,
    3. Nuta M. J.,
    4. de Kaste D.,
    5. Odekerken-Rombouts Y. M.,
    6. Vredenbregt M. J.,
    7. Weda M.,
    8. Barends D. M.

    Consistency of FMEA used in validation of analytical procedures. J. Pharm. Biomed. Anal. 2010, 54 (3), 592–595.

    OpenUrlPubMed
15. 15.↵
    1. Borman P.,
    2. Nethercote P.,
    3. Chatfield M.,
    4. Thompson D.,
    5. Truman K.

    The application of quality by design to analytical methods. Pharm. Technol. October 2, 2007.
16. 16.↵
    1. Duguid J.,
    2. Kielpinski G.,
    3. Seymour B.,
    4. du Moulin G.,
    5. Genzyme D.

    MYCOPLASMA TESTING—Risk assessment for a rapid mycoplasma test optimized for cell therapy products. Am. Pharm. Rev. 2009, 12 (6), 100–104.

    OpenUrl
17. 17.↵
    1. Zimmermann H. F.,
    2. Hentschel N.

    Proposal on how to conduct a biopharmaceutical process failure mode and effects analysis (FMEA) as a risk assessment tool. PDA J. Pharm. Sci. Technol. 2011, 65 (5), 506–512.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    Food Quality and Safety Systems—A Training Manual on Food Hygiene and the Hazard Analysis and Critical Control Point (HACCP) System, Section 3, Module 3, Food and Agriculture Organization of the United Nations: Rome, Italy, 1998; available at http://www.fao.org/docrep/W8088E/w8088e00.htm.
19. 19.↵
    Application of Hazard Analysis and Critical Control Point (HACCP) Methodology to Pharmaceuticals; WHO Technical Report Series 908, Annex 7; World Health Organization, 2003; available at http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/.
20. 20.↵
    General Principles of Food Hygiene, Codex alimentarius, Annex CAC/RCP 1, World Health Organization, Food and Agriculture Organization of the United Nations (2003; available at http://www.codexalimentarius.org” – Rev. 4 – 2003.
21. 21.↵
    1. Tartari R.

    Quality and Engineering Risk Management, 1st ed.; F. Angeli: Milan, Italy, 2009; pp 75–81.
22. 22.↵
    1. Pearson F. C.,
    2. Weary M.,
    3. Jorgensen J. H.

    Pyrogens: Endotoxins, LAL Testing, and Depyrogenation, 3rd ed.; Marcel Dekker: New York, 1985; pp 23–54.
23. 23.↵
    1. Jahnke M.,
    2. Kühn K. D.

    Use of the hazard analysis and critical control points (HACCP) risk assessment on a medical device for parenteral application. PDA J. Pharm. Sci. Technol. 2003, 57 (1), 32–42.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Chan T. C.

    A HACCP framework for risk management in bio/pharmaceutical processes. PDA Letter 2005, 41 (3), 13–18.

    OpenUrl
25. 25.↵
    1. Sandle T.

    Environmental monitoring risk assessment. J. GXP Compliance 2006, 10 (2), 1–20.

    OpenUrl
26. 26.
    Pharmaceutical Quality System (ICH Q10). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2008; available at http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
27. 27.
    Current Good Manufacturing Practice in Manufacturing, Processing, Packing or Holding of Drugs; General. Code of Federal Regulations, Title 21, Part 210; U.S. Food and Drug Administration; available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm